Could Horizon Pharma PLC Decline After Today’s Tip From Option Traders?

 Could Horizon Pharma PLC Decline After Today's Tip From Option Traders?

In today’s session Horizon Pharma PLC (HZNP) registered an unusually high (1,818) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious HZNP increase. With 1,818 contracts traded and 70244 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: HZNP170120C00017000 closed last at: $6.3 or 8.6% up. About 216,648 shares traded hands. Horizon Pharma PLC (NASDAQ:HZNP) has risen 43.68% since April 18, 2016 and is uptrending. It has outperformed by 39.25% the S&P500.

Horizon Pharma PLC (NASDAQ:HZNP) Ratings Coverage

Out of 9 analysts covering Horizon Pharma (NASDAQ:HZNP), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. $40 is the highest target while $21 is the lowest. The $28.33 average target is 30.25% above today’s ($21.75) stock price. Horizon Pharma has been the topic of 20 analyst reports since September 9, 2015 according to StockzIntelligence Inc. The rating was maintained by Mizuho on Monday, December 14 with “Buy”. The company was reinitiated on Wednesday, January 6 by Citigroup. Mizuho maintained it with “Buy” rating and $29 target price in Monday, October 31 report. The stock of Horizon Pharma PLC (NASDAQ:HZNP) has “Outperform” rating given on Wednesday, June 29 by BMO Capital Markets. Jefferies initiated the shares of HZNP in a report on Tuesday, January 19 with “Buy” rating. The firm has “Neutral” rating given on Tuesday, August 9 by Citigroup. As per Tuesday, November 10, the company rating was maintained by Mizuho. The company was maintained on Tuesday, May 10 by Mizuho. The firm has “Buy” rating by Jefferies given on Monday, November 23. Mizuho maintained the stock with “Buy” rating in Tuesday, November 8 report.

According to Zacks Investment Research, “Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company’s U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon’s global headquarters are in Dublin, Ireland.”

Insitutional Activity: The institutional sentiment increased to 1.46 in Q2 2016. Its up 0.25, from 1.21 in 2016Q1. The ratio is positive, as 46 funds sold all Horizon Pharma PLC shares owned while 45 reduced positions. 38 funds bought stakes while 72 increased positions. They now own 135.34 million shares or 2.87% less from 139.33 million shares in 2016Q1.
Grp Inc One Trading L P owns 162,856 shares or 0.03% of their US portfolio. Stifel Fincl Corporation owns 268,611 shares or 0.02% of their US portfolio. The Switzerland-based Swiss Bancshares has invested 0.01% in Horizon Pharma PLC (NASDAQ:HZNP). Systematic Financial Management Limited Partnership has 203,910 shares for 0.05% of their US portfolio. Ladenburg Thalmann Financial Services Inc accumulated 0.01% or 24,416 shares. Parkwood Ltd Liability Corp holds 0.28% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP) for 101,900 shares. The Florida-based Carl Domino Inc has invested 0.23% in Horizon Pharma PLC (NASDAQ:HZNP). Acadian Asset Mgmt Ltd Liability Co reported 624 shares or 0% of all its holdings. Quantitative Investment Limited Liability Co last reported 30,500 shares in the company. National Bank & Trust Of Montreal Can accumulated 0.01% or 618,861 shares. The New York-based Morgan Stanley has invested 0% in Horizon Pharma PLC (NASDAQ:HZNP). D E Shaw & has 927,514 shares for 0.03% of their US portfolio. Envestnet Asset Mngmt, a Illinois-based fund reported 120,329 shares. Susquehanna Grp Incorporated Llp has invested 0% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP). Clinton Grp holds 0.02% or 30,211 shares in its portfolio.

Insider Transactions: Since June 15, 2016, the stock had 0 buys, and 2 insider sales for $500,280 net activity. SHERMAN JEFFREY W also sold $58,000 worth of Horizon Pharma PLC (NASDAQ:HZNP) on Tuesday, August 2. Nohria Virinder had sold 25,000 shares worth $442,280 on Wednesday, June 15.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The company has a market cap of $3.51 billion. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It currently has negative earnings. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

HZNP Company Profile

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, incorporated on December 20, 2011, is a biopharmaceutical company. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. The Firm markets approximately nine medicines through its orphan, primary care and rheumatology business units. The Company’s segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. The Company’s marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Firm also developed DUEXIS and RAYOS, known as LODOTRA.

More notable recent Horizon Pharma PLC (NASDAQ:HZNP) news were published by: Fool.com which released: “Why Horizon Pharma PLC Jumped Higher Today” on November 07, 2016, also Fool.com with their article: “Why Horizon Pharma plc Stock Slumped in October” published on November 09, 2016, Fool.com published: “Why Allergan, Horizon Pharma plc, and Pfizer All Spiked Wednesday” on November 10, 2016. More interesting news about Horizon Pharma PLC (NASDAQ:HZNP) were released by: Seekingalpha.com and their article: “Horizon Pharma Plc (HZNP) Q3 2016 Results – Earnings Call Transcript” published on November 07, 2016 as well as Globenewswire.com‘s news article titled: “Horizon Pharma plc Selected as One of Chicago Tribune’s 2016 Top Workplaces” with publication date: November 11, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment